FCA consults on guidance for cannabis companies
In November 2018, the UK law was changed to allow specialist doctors to prescribe cannabis. Around the same time Canada legalised recreational cannabis. This change has prompted a growing interest in investment both here and overseas in cannabis derived products.
Such a change has led to a growing interest in cannabis products across the pharmaceutical industry, as well as the potential investment opportunities that it brings. This means that aside from medicinal use, there is now a evolving industry in respect of legal cannabis-derived products in the UK.
We advise on all aspects related to the cannabis industry. This includes advising corporates and individuals (both domestic and overseas) thinking about entering the medicinal/pharmaceutical cannabis industry in the UK or advising those based in the UK who are considering investing in cannabis industries in other jurisdictions.
Our advice is crucial to any individual or corporate interested in investing in the industry where recreational cannabis is lawful, as this may expose them to liability under the Proceeds of Crime Act 2002.
Our team of specialist lawyers is made up of experts from across the firm, who can advise on a variety of legal issues, including;
To date we have advised a number of corporates and individuals on cannabis related matters.
Skip to content Home About Us Insights Services Contact Accessibility